Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Total Liabilities (2016 - 2025)

UroGen Pharma's Total Liabilities history spans 10 years, with the latest figure at $305.9 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 3.88% year-over-year to $305.9 million; the TTM value through Dec 2025 reached $305.9 million, up 3.88%, while the annual FY2025 figure was $305.9 million, 3.88% up from the prior year.
  • Total Liabilities reached $305.9 million in Q4 2025 per URGN's latest filing, up from $300.5 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $305.9 million in Q4 2025 to a low of $20.9 million in Q1 2021.
  • Average Total Liabilities over 5 years is $216.4 million, with a median of $234.7 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: soared 773.63% in 2022, then increased 3.88% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $111.3 million in 2021, then surged by 102.08% to $225.0 million in 2022, then grew by 8.24% to $243.5 million in 2023, then rose by 20.94% to $294.5 million in 2024, then increased by 3.88% to $305.9 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Total Liabilities are $305.9 million (Q4 2025), $300.5 million (Q3 2025), and $302.1 million (Q2 2025).